Abstract
In the past, ABO blood group incompatibility was considered an absolute contraindication for kidney transplantation. Progress in defined desensitization practice and immunologic understanding has allowed increasingly successful ABO incompatible transplantation during recent years. This paper focused on the history, disserted outcomes, desensitization modalities and protocols, posttransplant immunologic surveillance, and antibody-mediated rejection in transplantation with an ABO incompatible kidney allograft. The mechanism underlying accommodation and antibody-mediated injury was also described.
Highlights
The most effective treatment of end-stage renal disease is kidney transplantation, but a severe donor shortage has significantly limited this treatment
To clarify the current status and uncertainties in this area, the present paper focuses on recently reported outcomes of ABO-incompatible kidney transplantation (ABOi KT), preconditioning methods before transplantation, posttransplant monitoring and management, diagnosis and treatment of antibody-mediated rejection, and the basic elucidation of immune tolerance and accommodation
As an extension of this idea, these have led to a modified protocol that consists of an antibody-depleting procedure and intravenous immunoglobulin with no long-term B-cell suppression from splenectomy or rituximab
Summary
The most effective treatment of end-stage renal disease is kidney transplantation, but a severe donor shortage has significantly limited this treatment. To overcome this profound donor shortage, immunologic barriers historically considered as absolute contraindications to transplantation are being reevaluated. One such barrier is the ABO blood group incompatibility. Through the help of a better understanding of related immunologic mechanisms and effective various regimens for controlling it, ABO-incompatible kidney transplantation (ABOi KT) is being performed with increasing frequency [5]. To clarify the current status and uncertainties in this area, the present paper focuses on recently reported outcomes of ABOi KT, preconditioning methods before transplantation, posttransplant monitoring and management, diagnosis and treatment of antibody-mediated rejection, and the basic elucidation of immune tolerance and accommodation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
